Skip to Main Content

An official website of the United States government

Principal Investigator
Name
Minal Kale
Degrees
MD
Institution
Icahn School of Medicine at Mount Sinai
Position Title
Assistant Professor
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-578
Initial CDAS Request Approval
Feb 7, 2020
Title
Personalizing Lung Cancer Screening for Smokers with Comorbidities
Summary
Lung cancer screening, consisting of an annual low-dose computed tomography (LDCT) is currently recommended to 8 million smokers who are at high risk of developing lung cancer. However, many individuals who are eligible for lung cancer screening also have comorbid conditions (such as chronic obstructive pulmonary disease [COPD], cardiovascular disease [CVD], and stroke) due to the shared risk factor with lung cancer (i.e., tobacco exposure). Others have comorbid diabetes mellitus (DM), another condition that is prevalent among middle aged and older individuals eligible for screening. These chronic conditions substantially alter the benefits from lung cancer screening by influencing risk of complications from work-up of positive screening tests.
Aims

1. Determine the impact of comorbidities on complications from diagnostic evaluation of a positive lung cancer screening test
2. Determine the impact of comorbidities on lung cancer treatment complications

Collaborators

Juan Wisnivesky, MD, DrPH Icahn School of Medicine at Mount Sinai
Joey Kong, PhD; MGH
Keith Sigel, MD, PhD; Icahn School of Medicine at Mount Sinai

Related Publications